Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Presentation THT 2025

Role of Molecular Biopsy in Precision Rejection Diagnosis

Presenter: Andrea Fernandez-Valledor

February 12, 2025

Presentation THT 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Presentation THT 2024

Heart Failure Diagnosis Using Wearable Devices

Presenter: Rohan Khera

March 05, 2024

Presentation THT 2024

Multimodal Imaging Is Needed for Early Diagnosis and Monitoring of Therapy

Presenter: Sharmila Dorbala

March 05, 2024

Presentation THT 2024

CCM Applied to Patients With HFpEF

Presenter: Javed Butler

March 04, 2024

Presentation THT 2024

Physiological Effects of Renal Denervation in Patients With HFpEF

Presenter: Karl-Philipp Rommel

March 04, 2024

Presentation THT 2024

Pericut: Pericardiotomy as a Therapy for HFpEF

Presenter: Barry Borlaug

March 04, 2024

Presentation THT 2024

Splanchnic Denervation in HFpEF

Presenter: Marat Fudim

March 04, 2024

Presentation THT 2024

Personalized Pacing for HFpEF: myPACE

Presenter: Markus Meyer

March 04, 2024

Presentation THT 2024

Overlap Between Valvular Heart Diseases and HFpEF

Presenter: Yogesh Reddy

March 04, 2024

Presentation THT 2024

Insights From Molecular Phenotyping in HFpEF

Presenter: Kavita Sharma

March 04, 2024

Presentation THT 2024

Mechanisms and Therapeutic Targets for Obesity-Related HFpEF

Presenter: Jennifer Ho

March 04, 2024

Presentation THT 2024

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Presenter: Sanjiv J. Shah

March 04, 2024

Presentation THT 2024

Atrial Functional MR: Diagnosis and Therapy Implications

Presenter: Federico M. Asch

March 04, 2024

News Conference News THT 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Yael L. Maxwell

March 22, 2023

Presentation THT 2023

EKG in the Screening, Diagnosis and Management of Heart Failure

Presenter: Pierre Elias

March 22, 2023

Presentation THT 2023

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

Presenter: Julie Rosenthal

March 21, 2023

Presentation THT 2023

Diagnosis and Classification of Pulmonary Hypertension in 2023

Presenter: Ryan Tedford

March 21, 2023

Presentation THT 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presenter: Charles Dow

March 20, 2023

Presentation THT 2023

To evaluate the effectiveness of the Mayo scoring system for predicting a diagnosis of TTR amyloidosis in a multi-racial community cohort.

Presenter: Karan Wats

March 20, 2023

Advertisement

Role of Molecular Biopsy in Precision Rejection Diagnosis

Determining Equity and Timeliness of ATTR-CM Diagnosis

Heart Failure Diagnosis Using Wearable Devices

Multimodal Imaging Is Needed for Early Diagnosis and Monitoring of Therapy

CCM Applied to Patients With HFpEF

Physiological Effects of Renal Denervation in Patients With HFpEF

Pericut: Pericardiotomy as a Therapy for HFpEF

Splanchnic Denervation in HFpEF

Personalized Pacing for HFpEF: myPACE

Overlap Between Valvular Heart Diseases and HFpEF

Insights From Molecular Phenotyping in HFpEF

Mechanisms and Therapeutic Targets for Obesity-Related HFpEF

HFpEF Diagnosis and Treatment: : Where Do We Stand in 2024?

Atrial Functional MR: Diagnosis and Therapy Implications

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

EKG in the Screening, Diagnosis and Management of Heart Failure

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

Diagnosis and Classification of Pulmonary Hypertension in 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

To evaluate the effectiveness of the Mayo scoring system for predicting a diagnosis of TTR amyloidosis in a multi-racial community cohort.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content